Andecaliximab
Modify Date: 2025-08-25 10:52:25
Andecaliximab structure
|
Common Name | Andecaliximab | ||
|---|---|---|---|---|
| CAS Number | 1518996-49-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AndecaliximabAndecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2]. |
| Name | Andecaliximab |
|---|
| Description | Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Andecaliximab 增加血清中 IL-7 的水平[1]。 Andecaliximab (50 μg/mL；24 h)减少 ABC 类细胞系的 SMAD2 磷酸化 (pSMAD2)[2]。 |
| In Vivo | Andecaliximab 改善肿瘤浸润 T 细胞内 T 细胞受体 (TCR) 的多样性[1]。 Andecaliximab (20 mg/kg；腹腔注射，单次) 在特发性肺纤维化的人源 NSG 小鼠模型中显示出抗纤维化功效[2]。 Animal Model: Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF[2] Dosage: 20 mg/kg Administration: Intraperitoneal injection; 20 mg/kg, once a week for once Result: Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations. |
| References |
| No Any Chemical & Physical Properties |